first large study of glp-1 receptor agonists during pregnancy Glucagon-like peptide-1 agonist use in pregnancy: a review GLP-1 Receptor Agonist Exposure During
Description
GLP-1RAs are considered safe and reduce the risk of severe hypoglycemia in patients with chronic kidney disease
BC analysis revealed that these changes were primarily driven by significant reductions in FBM and FBM percentage, while BMC and extracellular fluid balance remained unaffected
They reduce hemoglobin A 1c (HbA 1c ), weight, major cardiovascular events, and renal decline
These symptoms usually start to show up during the dose-escalation stages and get better as the treatment goes on
E.NauckM
51 This evidence suggest that Danuglipron demonstrates potential for glycemic control and weight reduction in T2DM with an acceptable safety profile
